July 2022

ASCO Spotlight With Ravi B. Parikh, MD, MPP: Can Nudges Increase the Number of Serious Illness Conversations in Community Oncology?

July 22, 2022

HEALTH POLICY & DELIVERY

Ravi B. Parikh, MD, MPP, assistant professor, Department of Medical Ethics and Health Policy and Medicine, Perelman School of Medicine, University of Pennsylvania, presented long-term results from an experiment with an algorithm designed to prompt oncologists to have serious illness conversations.

ASCO Spotlight With Hope S. Rugo, MD, FASCO, on Clinical Trial Minority Recruitment, PALOMA-2 Findings

July 21, 2022

BREAST CANCER

Hope S. Rugo, MD, FASCO, professor of medicine and director, Breast Oncology and Clinical Trials Education, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, said PALOMA-2 results don’t match what she has seen in practice.

ASCO Spotlight With Randall A. Oyer, MD: Clinical Trials Must Be Accessible to Everyone

July 21, 2022

ADVANCING HEALTH EQUITY

Randall A. Oyer, MD, medical director of the Ann B. Barshinger Cancer Institute, medical director of oncology, and medical director of the Cancer Risk Evaluation Program, Lancaster General Health, discusses recommendations to improve diversity in clinical trials.

Patients With Cancer Face Major Financial Roadblocks, Not All Concerning Out-of-Pocket Costs

July 07, 2022

HEALTH POLICY & DELIVERY

Abstracts presented at this year's American Society of Clinical Oncology Annual meeting detailed the financial hardships many patients with cancer face, including those related to high-deductible health plans and clinical trial participation.

FOENIX Update: A New Era in Cholangiocarcinoma Precision Medicine

July 01, 2022

SOLID TUMORS

Patients with iCCA, particularly those whose disease progresses following first-line chemotherapy, have limited overall treatment options. Data presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting show that patients may soon have a new agent to fight this rare cancer in futibatinib (Taiho Oncology), an FGFR inhibitor.

Challenging the “One-Size-Fits-All” Approach in Early MCL Treatment

June 19, 2022

BLOOD CANCERS

Anita Kumar, MD, medical oncologist with Memorial Sloan Kettering Cancer Center, led a session at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO), on New Directions in Mantle Cell Lymphoma.

ROSEWOOD: Zanubrutinib Combo Provides Superior Efficacy in FL

June 12, 2022

BLOOD CANCERS

A primary analysis of the phase 2 ROSEWOOD trial finds that a combination of zanubrutinib and obinutuzumab is superior to obinutuzumab alone in relapsed/refractory follicular lymphoma (FL). Results were presented at the 2022 European Hematology Association Congress.

Inovio's DNA Vaccine Combo Plus Cemiplimab Shows Promise in Glioblastoma

June 07, 2022

SOLID TUMORS

The results involve a pair of DNA medicines combined with cemiplimab, which is approved as Libtayo to treat other solid tumors. In this study, the regimen is designed to prime a T-cell response before a patient receives radiation.

ASCT Early in Multiple Myeloma Treatment Improves PFS, but OS Same as RVd

June 06, 2022

BLOOD CANCERS

Results presented at the American Society of Clinical Oncology Annual Meeting showed a 21.4-month advantage for autologous stem cell transplant (ASCT) over a common triplet therapy in progression-free survival (PFS) but no advantage in overall survival (OS).

Trastuzumab Deruxtecan Cuts Risk of Disease Progression or Death by 50% for Patients With HER2-Low Metastatic Breast Cancer

June 05, 2022

BREAST CANCER

Practice-changing data from the DESTINY-Breast04 study, presented during the 2022 Annual Meeting of the American Society of Clinical Oncology in Chicago, show that trastuzumab deruxtecan reduced the risk of disease progression or death by 50% compared with chemotherapy for human epidermal growth factor receptor-2 (HER2)–low patients with both hormone receptor (HR)–positive and HR-negative disease.

ASCO, WHO to Launch Global Quality Initiative in Cancer Care

June 04, 2022

ADVANCING HEALTH EQUITY

The collaboration, put in place through a Memorandum of Understanding, was presented Saturday in a keynote address by WHO Cancer Control Officer André Ilbawi, MD, during the presidential symposium at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago.

Over 6 Years, First-line Brentuximab Vedotin Cuts Risk of Death in Hodgkin Lymphoma by 41%

June 04, 2022

BLOOD CANCERS

Data presented at ASCO show that after 6 years, patients with advanced Hodgkin lymphoma who were treated with a combination of brentuximab vedotin and chemotherapy had a sharply reduced risk of death and a reduced risk of a secondary cancer.

SHINE: Adding Ibrutinib to Treatment Improves PFS by 50% for Older Patients With Mantle Cell Lymphoma

June 03, 2022

BLOOD CANCERS

Findings from the phase 3 SHINE trial could make ibrutinib the standard treatment option for older patients with mantle cell lymphoma (MCL), who often cannot tolerate chemotherapy or transplant strategies, according to study authors.